These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35212817)

  • 1. Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
    Zhao Q; Tong J; Liu X; Li S; Chen D; Miao L
    J Cancer Res Clin Oncol; 2022 May; 148(5):1269-1273. PubMed ID: 35212817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.
    Wang H; Yao Z; Kang K; Zhou L; Xiu W; Sun J; Xie C; Yu M; Li Y; Zhang Y; Zheng Y; Lin G; Pan X; Wu Y; Luo R; Wang L; Tang M; Liao S; Zhu J; Zhou X; Zhang X; Xu Y; Liu Y; Peng F; Wang J; Xiang L; Yin L; Deng L; Huang M; Gong Y; Zou B; Wang H; Wu L; Yuan Z; Bi N; Fan M; Xu Y; Tong R; Yi L; Gan L; Xue J; Mo X; Chen C; Na F; Lu Y
    Med; 2024 Oct; 5(10):1237-1254.e9. PubMed ID: 38964333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
    Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
    Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
    J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
    Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
    Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
    Front Immunol; 2022; 13():794251. PubMed ID: 35355980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Milenova I; Verhoeff J; Heiniö C; Zafar S; Garcia-Vallejo JJ; van Beusechem VW; de Gruijl TD; Kalervo A; Sorsa S; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():706517. PubMed ID: 34367166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
    Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
    Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
    Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
    Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
    Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
    Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
    Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
    Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
    Front Immunol; 2022; 13():961796. PubMed ID: 35911673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in immune checkpoint inhibitors therapy for small cell lung cancer.
    Li L; Liang Y; Yu M; Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Wang Z; Jia Y; Kong F
    Cancer Med; 2023 May; 12(10):11097-11106. PubMed ID: 36880420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers.
    Masemann D; Meissner R; Schied T; Lichty BD; Rapp UR; Wixler V; Ludwig S
    Oncoimmunology; 2021 Feb; 10(1):1885778. PubMed ID: 33643696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
    Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
    Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.